ZyCOV-D vaccine price to be revealed next week, supply begins mid-September: Group MD

ZyCOV-D vaccine price– The world’s first DNA-based vaccine for COVID-19 was approved to be administered to adults and children aged 12 years and above. It is also the second indigenous COVID vaccine in India after Covaxin.

New Delhi: Sharvil Pankajbhai Patel, managing director of Cadila Healthcare Ltd, briefed on plans to roll out ZyCOV-D vaccine doses on Saturday after the drugmaker received approval for the same.

India’s Comptroller General of Medicines on Friday granted emergency use approval for ZyCoV-D, Zydus Cadila’s COVID-19 vaccine which is the world’s first DNA vaccine against the coronavirus.

“Next week (we) will have details on the price of ZyCOV-D vaccine. Vaccine supply will begin in mid-September. We can increase vaccine production to 1 crore per month from October in the region. new production plant, “Dr. Sharvil Patel, MD, Zydus Group, was quoted by ANI news agency.

The effectiveness of our COVID-19 vaccine is over 66% and its effectiveness against the Delta variant is around 66%, he added.

The world’s first DNA-based vaccine for COVID-19 has been approved for use in adults and children aged 12 and older.

About ZyCoV-D

The vaccine is being developed in partnership with the Department of Biotechnology of the Government of India as part of the “COVID Suraksha Mission” and implemented by the Biotechnology Research Assistance Council (BIRAC).

This three-dose vaccine, when injected, produces the spike protein of the SARS-CoV-2 virus and triggers an immune response that plays a vital role in disease protection as well as viral clearance.

“The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to cope with mutations in the virus, such as those which are already occurring,” the biotechnology department of the ministry said. Science and Technology.

While most COVID vaccines require two doses or even a single dose, ZyCoV-D will be given in three doses – the first on day 0, the second on day 28, and the last on day 56.
The company previously said it also has a needle-free dispensing system, as opposed to traditional syringes.

ZyCoV-D is the sixth vaccine authorized for emergency use in India and is the second indigenous vaccine against COVID after Bharat Biotech’s Covaxin.

Earlier, the company also revealed that it was working on a two-dose vaccine.

ALSO READ: Study On Mixing Covishield and Covaxin By CMC Vellore Gets DCGI Approval

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top